Bradley A Edwards1,2,3, Christopher Andara2, Shane Landry2, Scott A Sands1,4, Simon A Joosten5,6, Robert L Owens1,7, David P White1, Garun S Hamilton5,6, Andrew Wellman1. 1. 1 Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. 2 Sleep and Circadian Medicine Laboratory, Department of Physiology. 3. 3 School of Psychological Sciences and Monash Institute of Cognitive and Clinical Neurosciences, and. 4. 4 Department of Allergy, Immunology and Respiratory Medicine and Central Clinical School, The Alfred and Monash University, Melbourne, Victoria, Australia. 5. 6 School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia. 6. 5 Monash Lung and Sleep, Monash Medical Centre, Clayton, Victoria, Australia; and. 7. 7 Division of Pulmonary and Critical Care Medicine, University of California San Diego, San Diego, California.
Abstract
RATIONALE: Oral appliances (OAs) are commonly used as an alternative treatment to continuous positive airway pressure for patients with obstructive sleep apnea (OSA). However, OAs have variable success at reducing the apnea-hypopnea index (AHI), and predicting responders is challenging. Understanding this variability may lie with the recognition that OSA is a multifactorial disorder and that OAs may affect more than just upper-airway anatomy/collapsibility. OBJECTIVES: The objectives of this study were to determine how OA alters AHI and four phenotypic traits (upper-airway anatomy/collapsibility and muscle function, loop gain, and arousal threshold), and baseline predictors of which patients gain the greatest benefit from therapy. METHODS: In a randomized crossover study, 14 patients with OSA attended two sleep studies with and without their OA. Under each condition, AHI and the phenotypic traits were assessed. Multiple linear regression was used to determine independent predictors of the reduction in AHI. MEASUREMENTS AND MAIN RESULTS:OA therapy reduced the AHI (30 ± 5 vs. 11 ± 2 events/h; P < 0.05), which was driven by improvements in upper-airway anatomy/collapsibility under passive (1.9 ± 0.7 vs. 4.7 ± 0.6 L/min; P < 0.005) and active conditions (2.4 ± 0.9 vs. 6.2 ± 0.4 L/min; P < 0.001). No changes were seen in muscle function, loop gain, or the arousal threshold. Using multivariate analysis, baseline passive upper-airway collapsibility and loop gain were independent predictors of the reduction in AHI (r2 = 0.70; P = 0.001). CONCLUSIONS: Our findings suggest that OA therapy improves the upper-airway collapsibility under passive and active conditions. Importantly, a greater response to therapy occurred in those patients with a mild anatomic compromise and a lower loop gain.
RCT Entities:
RATIONALE: Oral appliances (OAs) are commonly used as an alternative treatment to continuous positive airway pressure for patients with obstructive sleep apnea (OSA). However, OAs have variable success at reducing the apnea-hypopnea index (AHI), and predicting responders is challenging. Understanding this variability may lie with the recognition that OSA is a multifactorial disorder and that OAs may affect more than just upper-airway anatomy/collapsibility. OBJECTIVES: The objectives of this study were to determine how OA alters AHI and four phenotypic traits (upper-airway anatomy/collapsibility and muscle function, loop gain, and arousal threshold), and baseline predictors of which patients gain the greatest benefit from therapy. METHODS: In a randomized crossover study, 14 patients with OSA attended two sleep studies with and without their OA. Under each condition, AHI and the phenotypic traits were assessed. Multiple linear regression was used to determine independent predictors of the reduction in AHI. MEASUREMENTS AND MAIN RESULTS: OA therapy reduced the AHI (30 ± 5 vs. 11 ± 2 events/h; P < 0.05), which was driven by improvements in upper-airway anatomy/collapsibility under passive (1.9 ± 0.7 vs. 4.7 ± 0.6 L/min; P < 0.005) and active conditions (2.4 ± 0.9 vs. 6.2 ± 0.4 L/min; P < 0.001). No changes were seen in muscle function, loop gain, or the arousal threshold. Using multivariate analysis, baseline passive upper-airway collapsibility and loop gain were independent predictors of the reduction in AHI (r2 = 0.70; P = 0.001). CONCLUSIONS: Our findings suggest that OA therapy improves the upper-airway collapsibility under passive and active conditions. Importantly, a greater response to therapy occurred in those patients with a mild anatomic compromise and a lower loop gain.
Authors: Bradley A Edwards; Andrew Wellman; Scott A Sands; Robert L Owens; Danny J Eckert; David P White; Atul Malhotra Journal: Sleep Date: 2014-07-01 Impact factor: 5.849
Authors: Kate Sutherland; Olivier M Vanderveken; Hiroko Tsuda; Marie Marklund; Frederic Gagnadoux; Clete A Kushida; Peter A Cistulli Journal: J Clin Sleep Med Date: 2014-02-15 Impact factor: 4.062
Authors: Andrey Zinchuk; Bradley A Edwards; Sangchoon Jeon; Brian B Koo; John Concato; Scott Sands; Andrew Wellman; Henry K Yaggi Journal: J Clin Sleep Med Date: 2018-05-15 Impact factor: 4.062
Authors: Shane A Landry; Simon A Joosten; Scott A Sands; David P White; Atul Malhotra; Andrew Wellman; Garun S Hamilton; Bradley A Edwards Journal: Respirology Date: 2017-04-13 Impact factor: 6.424
Authors: Ludovico Messineo; Luigi Taranto-Montemurro; Ali Azarbarzin; Melania D Oliveira Marques; Nicole Calianese; David P White; Andrew Wellman; Scott A Sands Journal: J Physiol Date: 2018-07-06 Impact factor: 5.182
Authors: Diego R Mazzotti; Diane C Lim; Kate Sutherland; Lia Bittencourt; Jesse W Mindel; Ulysses Magalang; Allan I Pack; Philip de Chazal; Thomas Penzel Journal: Physiol Meas Date: 2018-09-13 Impact factor: 2.833
Authors: Scott A Sands; Bradley A Edwards; Philip I Terrill; James P Butler; Robert L Owens; Luigi Taranto-Montemurro; Ali Azarbarzin; Melania Marques; Lauren B Hess; Erik T Smales; Camila M de Melo; David P White; Atul Malhotra; Andrew Wellman Journal: Eur Respir J Date: 2018-09-27 Impact factor: 16.671
Authors: Cathy A Goldstein; Richard B Berry; David T Kent; David A Kristo; Azizi A Seixas; Susan Redline; M Brandon Westover Journal: J Clin Sleep Med Date: 2020-04-15 Impact factor: 4.062